Voyager Therapeutics, Inc. logo VYGR - Voyager Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 17
HOLD 4
SELL 0
STRONG
SELL 0
| PRICE TARGET: $14.40 DETAILS
HIGH: $18.00
LOW: $8.00
MEDIAN: $18.00
CONSENSUS: $14.40
UPSIDE: 339.69%

Stock News

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026

- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented six-month good laboratory practice (GLP) toxicology data for VY1706, the Company's investigational gene therapy targeting intracellular and extracellular tau for Alzheimer's disease (AD), in a Developing Topics (late-breaking) poster presentation at the Alzheimer's Association International Conference (AAIC) taking place in London, July 12-15, 2026.

Jul 13, 2026 04:01 AM • globenewswire.com
Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer's Association International Conference (AAIC) taking place in London, July 12-15, 2026. The Developing Topics poster presentation will feature VY1706, Voyager's investigational gene therapy targeting intracellular and extracellular tau for Alzheimer's disease (AD). Earlier this month, Voyager received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early AD, with dosing expected to begin in the second half of the year.

Jun 29, 2026 04:01 AM • globenewswire.com
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

LEXINGTON, Mass. , June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer's Association International Conference (AAIC) taking place in London, July 12-15, 2026.

Jun 29, 2026 04:01 AM • globenewswire.com
UNLOCKING SPACE: Elon Musk is BREAKING RECORDS for orbital launches

UNLOCKING SPACE: Elon Musk is BREAKING RECORDS for orbital launches

Voyager Technologies Chairman and CEO Dylan Taylor joins ‘Mornings with Maria' to discuss SpaceX's record-breaking IPO, the rise of the space economy and Voyager's first year as a public company. #foxbusiness #morningswithmaria 0:00 SpaceX's Record-Breaking $75 Billion IPO Debut 1:07 Why Investors Are Betting Big on the Space Economy 3:15 Starlab's Race to Replace the International Space Station 5:23 The Growing Space Competition With China 6:48 Voyager's Astrobotic Deal and the Return to the Moon

Jun 12, 2026 09:15 AM • youtube.com
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference.

Jun 11, 2026 12:01 PM • globenewswire.com
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease

- Dosing of adults with early Alzheimer's disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses an IV-delivered, brain-targeted capsid to reduce intracellular and extracellular tau - LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for VY1706, the Company's investigational gene therapy targeting intracellular and extracellular tau for Alzheimer's disease (AD).

Jun 01, 2026 04:00 AM • globenewswire.com
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026

- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented three-month good laboratory practice (GLP) toxicology data for VY1706, the Company's investigational tau silencing gene therapy for Alzheimer's disease (AD), in a late-breaking presentation at the American Society of Gene & Cell Therapy's (ASGCT) 2026 Annual Meeting in Boston, May 11-15, 2026.

May 13, 2026 02:01 AM • globenewswire.com
Voyager Reports First Quarter 2026 Financial and Operating Results

Voyager Reports First Quarter 2026 Financial and Operating Results

- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - - Ended Q1 2026 with cash position of $172 million, runway into 2028 - LEXINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported first quarter 2026 financial and operating results.

May 07, 2026 12:01 PM • globenewswire.com
Reviewing Longeveron (NASDAQ:LGVN) & Voyager Therapeutics (NASDAQ:VYGR)

Reviewing Longeveron (NASDAQ:LGVN) & Voyager Therapeutics (NASDAQ:VYGR)

Longeveron (NASDAQ: LGVN - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability. Risk and Volatility Longeveron has a beta of

Apr 13, 2026 09:09 PM • defenseworld.net
Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026

Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026

Voyager Therapeutics maintains a "Strong Buy" rating as it approaches a pivotal 2026 catalyst with tau PET imaging data from its phase 1b study in Alzheimer's disease. Company's anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD, enabling advancement to phase 1b MAD in early AD patients. Company's robust cash position, projected to fund operations into 2028, is further supported by potential $2.4B in milestone payments and ongoing collaborations.

Apr 12, 2026 11:28 PM • seekingalpha.com
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -  - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 - - Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile - - Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 - LEXINGTON, Mass.

Mar 09, 2026 12:01 PM • globenewswire.com
Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028

Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028

Voyager Therapeutics (NASDAQ: VYGR) outlined what CEO Al Sandrock described as three "pillars of value" for the year ahead during a discussion at Oppenheimer's 36th Annual Life Science Conference, pointing to advancing two tau-directed programs, initiating two gene therapy clinical entries using its blood-brain barrier-penetrant capsids, and building out its emerging NeuroShuttle platform for brain delivery

Mar 02, 2026 12:05 AM • defenseworld.net
Contrasting Voyager Therapeutics (NASDAQ:VYGR) and Alvotech (NASDAQ:ALVO)

Contrasting Voyager Therapeutics (NASDAQ:VYGR) and Alvotech (NASDAQ:ALVO)

Alvotech (NASDAQ: ALVO - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability. Insider and Institutional Ownership 48.0% of Voyager Therapeutics

Jan 17, 2026 09:24 PM • defenseworld.net

Price Targets